MicroRNAs are short (21-25 nucleotides) non-coding RNA molecules that regulate gene expression by activating or repressing mRNA transcription. About 2000 have been identified thus far (Kozomara et al. Nucleic Acids Res 2019;47:155-162), and many have potential utility as biomarkers in the diagnosis, monitoring and treatment of multiple sclerosis. Read More
Neurology
FDA approves anti-amyloid therapy for Alzheimer’s disease
August 17, 2023Anti-amyloid therapy for Alzheimer’s disease has received renewed encouragement with the recent FDA approval of the second-generation monoclonal antibody lecanemab and the pending approval of donanemab. Read More
Novel biomarkers in development for MS
August 14, 2023Neurofilament-light chain (NfL) and glial fibrillary acidic protein (GFAP) are two of the main fluid biomarkers currently being examined for their clinical utility in evaluating disease activity, progression and treatment response. However, there are a number of other biomarkers under investigation. The following is a summary of some of the more promising candidates (reviewed in Maroto-Garcia et al. Clin Chim Acta 2023;548:117471). Read More
sNfL a useful alternative to gadolinium
July 31, 2023The prospective REDUCE-GAD study reports that higher serum neurofilament-light chain (NfL) levels are associated with the presence of contrast-enhancing (CE) lesions, which may enable clinicians to forego contrast agents for follow-up MRIs (Schaefer et al. Eur J Neurol 2023;30:2393-2400). Read More
Revised recommendations on the differential diagnosis of MS
July 25, 2023The Multiple Sclerosis Differential Diagnosis Consortium has published consensus recommendations on the differential diagnosis of multiple sclerosis (Solomon et al. Lancet Neurol 2023;22:750-768). This version updates recommendations published 15 years ago (Miller et al. Mult Scler 2008;14:1157-1174). Read More